Rezivertinib
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Aug 16, 2017 (NCT03386955)
Timeline
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1OCCN(C)C- Mol. weight
- 486.58 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314952 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04135820 | Phase 1 | Nov 30, 2019 | Beta Pharma, Inc., Jiao Tong University |
| NCT04135833 | Phase 1 | Nov 30, 2019 | Beta Pharma, Inc., Jiao Tong University |
| NCT03866499 | Phase 3 | May 31, 2019 | Beta Pharma, Inc., Chinese Academy of Medical Sciences |
| NCT03812809 | Phase 2 | Apr 1, 2019 | Beta Pharma, Inc., Chinese Academy of Medical Sciences |
| NCT03386955 | Phase 1 | Aug 16, 2017 | Beta Pharma, Inc., Chinese Academy of Medical Sciences |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beta Pharma, Inc. | For profit | 5 | 5 | 3 | 2017 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 3 | 0 | 3 | 2017 |
| Jiao Tong University | Academic/Hospital | 2 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1